Target Validation Pathfinder Grant
15 April 2020
Up to £50,000
The Target Validation Pathfinder Grant scheme provides funds for small, translational research projects that show potential for an application to the Dementia Consortium or collaboration with the ARUK Drug Discovery Alliance.
Duration: Up to 12 months.
Alzheimer’s Research UK has developed two strategic initiatives to support the discovery of new therapeutics for dementia, covering preclinical target validation and early phase drug discovery.
The ARUK Drug Discovery Alliance (DDA) is a network of Drug Discovery Institutes (DDIs) embedded within the Universities of Cambridge, Oxford and University College London. The DDA will take advantage of new science in neurodegenerative diseases that cause dementia from within the academic Institutions and elsewhere and rapidly translate this to novel drug discovery projects and/or novel biomarkers with clinical or diagnostic utility.
The Dementia Consortium brings together ARUK, Charles River, Evotec and seven pharmaceutical companies, Abbvie, Astex, Eisai, Johnson & Johnson, Lilly, MSD and Takeda, to support drug discovery and pharmacological validation of novel molecular targets and expedite the development of new drugs for dementia. The Dementia Consortium provides funding, resources and expertise both to increase the number of, and capitalise upon, new drug targets emerging from across the academic sector. Any promising drug targets will then be made available to any of the Pharma partners.
There are both similarities and differences between the work of the Drug Discovery Alliance and the Dementia Consortium. ARUK wishes to see different options available for researchers and their individual preferences or circumstances.
It is recognised that researchers may have promising data / projects which are too preliminary to progress with either the Drug Discovery Alliance or the Dementia Consortium. The Target Validation Pathfinder grant scheme (TVPG) is designed to support translational research that shows potential for an application to the Dementia Consortium or collaboration with the ARUK Drug Discovery Alliance, but would benefit from funding for preliminary, early-stage target validation work or feasibility studies to establish the viability of an approach.
Provided to cover salaries (research, technical, students etc), equipment, animal costs and running costs (consumables, travel etc).
For more information about any of the grant schemes or the application process please contact the Research Team email@example.com or 0300 111 5555
Applicants will be notified of the decision early February 2021
The lead applicant and point of contact must be based in an academic/research institution, either in the UK or abroad. Co-applicants from small and medium enterprises are permitted.
If the project requires ethical approval and/or Home Office licences or equivalent, the award is dependent upon the requisite approvals being granted.
The Lead applicant is expected to have a contract (fixed term or tenure) which covers the proposed duration of the grant. If the Lead applicant does not hold a tenure appointment, the application must include a co-applicant that does.
Applicants seeking to obtain preliminary data before a collaboration with one or more of ARUK’s Drug Discovery Institutes are required to hold early discussions with either one of the DDI Chief Scientific Officers (CSOs) regarding the suitability of the target and the data that is necessary to obtain before further work is initiated. A letter of support for the TVPG work plan will be required of the collaborating DDI CSO(s) with the application.
Applicants aiming to gain preliminary data to support an Expression of Interest submission to the Dementia Consortium are not required to obtain a letter of support from Evotec. However, applicants will be asked to justify how the outcomes of their proposals would fit within the remit of a future Dementia Consortium project.
TVPG applications will be viewed favourably if they follow a rejection from a prior Dementia Consortium submission where the feedback encouraged further experimental work to support their proposal. In such cases, the Consortium feedback will explicitly suggest applying for a TVPG to address the points raised and this feedback should be cited in the TVPG submission.
This scheme is not designed to cover:
- Pilot projects with no translational endpoint that could be taken up by one of ARUK’s regular grant schemes
- Bridging funds for staff between posts/funding (ARUK Network members can apply to Network Support grants)
- Extensions of current ARUK project grants (ARUK Major Project grant holders can apply to Extension grants).
Clinical trials and add-ons should be applied for through the Global Clinical Trials Fund. Drug discovery and development work should be applied for through the Dementia Consortium or through ARUK’s Drug Discovery Institutes.
See our Eligibility Guidelines for further information.
Applications are made via our grant application website.
Grant schemes only appear on this website when the round is open and we are accepting new applications.
Alzheimer’s Research UK is a member of the Association of Medical Research Charities and follows their guidelines for best practice in peer review. Grants are awarded entirely on scientific merit in relation to Alzheimer’s Research UK’s remit and on the basis of open competition. The quality of the application and applicants is the key determinant of outcome, although the strength of the dementia research environment within the institution is also considered.
For applications reviewed at GRB meetings:
Discussion in meeting
Each application is allocated to two GRB members, based roughly on their areas of expertise. The two members will present the application to the rest of the Board, including any relevant information from external reviews or applicant responses. A short discussion will follow before the GRB score the application. Applications for each grant scheme are ranked by their average score and recommendations for funding are made.
Those applications recommended for funding by the GRB are presented to the Trustees for final approval.
For applications reviewed outside of GRB meeting:
All GRB members are asked to read the application and associated documents and give a yes/no decision for whether or not the application should be funded giving comments.
A subgroup of the GRB hold a teleconference to discuss the application and the comments raised and a decision is reached.
Those applications recommended for funding by the GRB are presented to the trustees for final approval.
In the last three years Alzheimer’s Research UK has received 20 applications for Target Validation Pathfinder Grants. 8 of these projects were awarded funding.
The terms and conditions of grant differ for each grant scheme and contracts are drawn up individually once the grants have been awarded.
All grant holders are expected to report on the progress of their project on a regular basis. Read more about our reporting requirements on the measuring impact page.
Download our GDPR statement that explains how Alzheimer’s Research UK Research Team handles personal data about our grant applications and the rights that applicants have under data protection law. In this Notice, we refer to this type of information as “Applicant Data”.
Download our Bullying and Harassment policy that explains how Alzheimer’s Research UK Research Team handles allegations of bullying or harassment involving any of our grant participants.
These statements apply to applications submitted via Grant Tracker. They also apply to applications summitted via other means, such as by post and email.